Novo Nordisk has launched the first GLP-1 weight-loss pill in the US at a lower price than injections. The once-daily Wegovy pill recently received US regulatory approval and is now available nationwide. It is the only pill version that mimics the GLP-1 hormone to suppress appetite. Self-pay patients can access the starting dose for $149 per month, far below injectable list prices. The launch accelerates price competition with rival Eli Lilly, maker of Mounjaro and Zepbound. Novo hopes the pill’s lower cost and needle-free format will expand access for obesity treatment. The drug is currently approved only in the US, with UK approval under review.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War
By OMN AI
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
Add A Comment
